+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies?



Cardiac protection via metabolic modulation: an emerging role for incretin-based therapies?



Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 319-324



Cardiovascular disease continues to be a major cause of morbidity and mortality in patients with Type 2 Diabetes Mellitus. Whilst a focus on improved glucose control and HbA1c has led to a reduction in the progression and development of microvascular complications, the potential for this strategy to reduce cardiovascular event rates is less clearly defined. Identification of the incretin axis has facilitated the development of several novel therapeutic agents which target glucagon-like peptide-1 (GLP-1) pathways. The effects on glucose homeostasis are now established, but there is also now an increasing body of evidence to support a number of pleiotropic effects on the heart that may have the potential to influence cardiovascular outcomes. In this article, we review myocardial energy metabolism with particular emphasis on the potential benefits associated with a shift towards increased glucose utilisation and present the pre-clinical and clinical evidence regarding incretin effects on the heart. In addition we discuss the potential mechanism of action and benefit of drugs that modulate GLP-1 in patients with type 2 diabetes mellitus and coronary artery disease.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 051942128

Download citation: RISBibTeXText

PMID: 22827290


Related references

Cardiac Protection via Metabolic Modulation An Emerging Role for Incretin-Based Therapies?. Cardiovascular & Hematological Agents in Medicinal Chemistry 10(4): 319-324, 2012

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. American Journal of Medicine 123(7): S2-S10, 2010

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S20-S27, 2010

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2013

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S10-S19, 2010

Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Therapy 2(3): 146-161, 2011

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience. Internal Medicine Journal 41(4): 299-307, 2012

Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Journal of the American Academy of Nurse Practitioners 20 Suppl 1: 7-11, 2009

Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. Journal of the American Osteopathic Association 114(5 Suppl 2): S6-13, 2015

The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetologica 48(3): 219-225, 2011

Incretin-based therapies: a clinical need filled by unique metabolic effects. Diabetes Educator 32 Suppl 2: 65s-71s, 2006

Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. Journal of Pathology 238(2): 345-358, 2016